Review



human nsclc cell line wt for egfr  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human nsclc cell line wt for egfr
    a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of <t>EGFR,</t> ERK, and AKT in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in ( b ) and ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.
    Human Nsclc Cell Line Wt For Egfr, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 35523 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human nsclc cell line wt for egfr/product/ATCC
    Average 99 stars, based on 35523 article reviews
    human nsclc cell line wt for egfr - by Bioz Stars, 2026-03
    99/100 stars

    Images

    1) Product Images from "TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR -mutated lung cancer"

    Article Title: TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR -mutated lung cancer

    Journal: NPJ Precision Oncology

    doi: 10.1038/s41698-024-00557-2

    a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of EGFR, ERK, and AKT in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in ( b ) and ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.
    Figure Legend Snippet: a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of EGFR, ERK, and AKT in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in ( b ) and ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.

    Techniques Used: Western Blot, Control, Colorimetric Assay

    a Time course of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cell number during treatment with 1 μM osimertinib for up to 28 days. b Time course for the development of osimertinib resistance in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. The concentration of osimertinib was gradually increased from 10 nM to 1 μM each time the cells achieved 70% confluence. Immunoblot analysis of EGFR signaling as well as of p53 and p21 during treatment with 1 μM osimertinib for up to 72 h for osimertinib-resistant PC9/p53 GOF cells ( c ) and PC9/p53 EV and PC9/p53 WT cells that had been previously treated with osimertinib for 30 days ( d ). Data in ( a ) and ( b ) are means ± SEM for triplicates from one experiment and are representative of two independent experiments.
    Figure Legend Snippet: a Time course of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cell number during treatment with 1 μM osimertinib for up to 28 days. b Time course for the development of osimertinib resistance in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. The concentration of osimertinib was gradually increased from 10 nM to 1 μM each time the cells achieved 70% confluence. Immunoblot analysis of EGFR signaling as well as of p53 and p21 during treatment with 1 μM osimertinib for up to 72 h for osimertinib-resistant PC9/p53 GOF cells ( c ) and PC9/p53 EV and PC9/p53 WT cells that had been previously treated with osimertinib for 30 days ( d ). Data in ( a ) and ( b ) are means ± SEM for triplicates from one experiment and are representative of two independent experiments.

    Techniques Used: Concentration Assay, Western Blot

    Percentage cell number for PC9/p53 GOF mutant cells ( a ) as well as PC9/p53 EV , PC9/p53 WT , and PC9/p53 V218del cells ( b ) treated with 1 μM osimertinib (Osi) in the absence or presence of infliximab (1 µg/ml) for the indicated times. Viability of osimertinib-resistant PC9/p53 R248Q ( c ) and PC9/p53 R273H ( d ) cells treated with the indicated concentrations of osimertinib in the absence or presence of infliximab (1 µg/ml) for 72 h as measured by a colorimetric assay. e Immunoblot analysis of EGFR signaling as well as p53 and c-Myc expression in osimertinib-resistant PC9/p53 GOF mutant cells incubated in the absence or presence of osimertinib (100 nM) or infliximab (1 µg/ml) for 24 h. Data in ( a ) through ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.
    Figure Legend Snippet: Percentage cell number for PC9/p53 GOF mutant cells ( a ) as well as PC9/p53 EV , PC9/p53 WT , and PC9/p53 V218del cells ( b ) treated with 1 μM osimertinib (Osi) in the absence or presence of infliximab (1 µg/ml) for the indicated times. Viability of osimertinib-resistant PC9/p53 R248Q ( c ) and PC9/p53 R273H ( d ) cells treated with the indicated concentrations of osimertinib in the absence or presence of infliximab (1 µg/ml) for 72 h as measured by a colorimetric assay. e Immunoblot analysis of EGFR signaling as well as p53 and c-Myc expression in osimertinib-resistant PC9/p53 GOF mutant cells incubated in the absence or presence of osimertinib (100 nM) or infliximab (1 µg/ml) for 24 h. Data in ( a ) through ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.

    Techniques Used: Mutagenesis, Colorimetric Assay, Western Blot, Expressing, Incubation



    Similar Products

    human nsclc cell line wt for egfr  (ATCC)
    99
    ATCC human nsclc cell line wt for egfr
    a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of <t>EGFR,</t> ERK, and AKT in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in ( b ) and ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.
    Human Nsclc Cell Line Wt For Egfr, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human nsclc cell line wt for egfr/product/ATCC
    Average 99 stars, based on 1 article reviews
    human nsclc cell line wt for egfr - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of EGFR, ERK, and AKT in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in ( b ) and ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.

    Journal: NPJ Precision Oncology

    Article Title: TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR -mutated lung cancer

    doi: 10.1038/s41698-024-00557-2

    Figure Lengend Snippet: a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of EGFR, ERK, and AKT in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in ( b ) and ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.

    Article Snippet: Five human NSCLC cell lines with EGFR activating mutations (PC-9 [ECACC #90071810], H1975 [ATCC #CRL-5908], II-18 [#RCB2093; RIKEN BioResource Research Center, Tsukuba, Japan], HCC827 [ATCC #CRL-2868], and HCC4006 [ATCC #CRL-2871]) and one human NSCLC cell line WT for EGFR (A549 [ATCC #CCL-185]) were studied.

    Techniques: Western Blot, Control, Colorimetric Assay

    a Time course of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cell number during treatment with 1 μM osimertinib for up to 28 days. b Time course for the development of osimertinib resistance in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. The concentration of osimertinib was gradually increased from 10 nM to 1 μM each time the cells achieved 70% confluence. Immunoblot analysis of EGFR signaling as well as of p53 and p21 during treatment with 1 μM osimertinib for up to 72 h for osimertinib-resistant PC9/p53 GOF cells ( c ) and PC9/p53 EV and PC9/p53 WT cells that had been previously treated with osimertinib for 30 days ( d ). Data in ( a ) and ( b ) are means ± SEM for triplicates from one experiment and are representative of two independent experiments.

    Journal: NPJ Precision Oncology

    Article Title: TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR -mutated lung cancer

    doi: 10.1038/s41698-024-00557-2

    Figure Lengend Snippet: a Time course of PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cell number during treatment with 1 μM osimertinib for up to 28 days. b Time course for the development of osimertinib resistance in PC9/p53 EV , PC9/p53 WT , and PC9/p53 MUT cells. The concentration of osimertinib was gradually increased from 10 nM to 1 μM each time the cells achieved 70% confluence. Immunoblot analysis of EGFR signaling as well as of p53 and p21 during treatment with 1 μM osimertinib for up to 72 h for osimertinib-resistant PC9/p53 GOF cells ( c ) and PC9/p53 EV and PC9/p53 WT cells that had been previously treated with osimertinib for 30 days ( d ). Data in ( a ) and ( b ) are means ± SEM for triplicates from one experiment and are representative of two independent experiments.

    Article Snippet: Five human NSCLC cell lines with EGFR activating mutations (PC-9 [ECACC #90071810], H1975 [ATCC #CRL-5908], II-18 [#RCB2093; RIKEN BioResource Research Center, Tsukuba, Japan], HCC827 [ATCC #CRL-2868], and HCC4006 [ATCC #CRL-2871]) and one human NSCLC cell line WT for EGFR (A549 [ATCC #CCL-185]) were studied.

    Techniques: Concentration Assay, Western Blot

    Percentage cell number for PC9/p53 GOF mutant cells ( a ) as well as PC9/p53 EV , PC9/p53 WT , and PC9/p53 V218del cells ( b ) treated with 1 μM osimertinib (Osi) in the absence or presence of infliximab (1 µg/ml) for the indicated times. Viability of osimertinib-resistant PC9/p53 R248Q ( c ) and PC9/p53 R273H ( d ) cells treated with the indicated concentrations of osimertinib in the absence or presence of infliximab (1 µg/ml) for 72 h as measured by a colorimetric assay. e Immunoblot analysis of EGFR signaling as well as p53 and c-Myc expression in osimertinib-resistant PC9/p53 GOF mutant cells incubated in the absence or presence of osimertinib (100 nM) or infliximab (1 µg/ml) for 24 h. Data in ( a ) through ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.

    Journal: NPJ Precision Oncology

    Article Title: TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR -mutated lung cancer

    doi: 10.1038/s41698-024-00557-2

    Figure Lengend Snippet: Percentage cell number for PC9/p53 GOF mutant cells ( a ) as well as PC9/p53 EV , PC9/p53 WT , and PC9/p53 V218del cells ( b ) treated with 1 μM osimertinib (Osi) in the absence or presence of infliximab (1 µg/ml) for the indicated times. Viability of osimertinib-resistant PC9/p53 R248Q ( c ) and PC9/p53 R273H ( d ) cells treated with the indicated concentrations of osimertinib in the absence or presence of infliximab (1 µg/ml) for 72 h as measured by a colorimetric assay. e Immunoblot analysis of EGFR signaling as well as p53 and c-Myc expression in osimertinib-resistant PC9/p53 GOF mutant cells incubated in the absence or presence of osimertinib (100 nM) or infliximab (1 µg/ml) for 24 h. Data in ( a ) through ( d ) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.

    Article Snippet: Five human NSCLC cell lines with EGFR activating mutations (PC-9 [ECACC #90071810], H1975 [ATCC #CRL-5908], II-18 [#RCB2093; RIKEN BioResource Research Center, Tsukuba, Japan], HCC827 [ATCC #CRL-2868], and HCC4006 [ATCC #CRL-2871]) and one human NSCLC cell line WT for EGFR (A549 [ATCC #CCL-185]) were studied.

    Techniques: Mutagenesis, Colorimetric Assay, Western Blot, Expressing, Incubation